natgillin/translations-raw huggingface dataset:
A polypeptide comprising (i) a MeCP2 protein or biologically active fragment or a derivative of said protein or fragment, and (ii) a protein transduction domain, wherein the MeCP2 protein is fused to the protein transduction domain, for use in a method of treating Rett syndrome; wherein said fragment comprises at least 150 amino acids of the MeCP2 protein; and wherein said derivative of said protein or fragment has at least 60 % identity with said MeCP2 protein or fragment thereof; and wherein said fragment or said derivative has at least 60 % of said biological activity, as determined by an in vitro transcription assay described by Nan, X et al., Cell 88: 471-481 (1997). 
Polipeptid, koji sadrži (i) protein MeCP2 ili biološki aktivni fragment ili derivat spomenutog proteina ili fragmenta, i (ii) domenu transdukcije proteina, pri čemu je protein MeCP2 sjedinjen s domenom transdukcije proteina, naznačen time, da se upotrebljava u postupku liječenja Rett-sindroma; pri čemu spomenuti fragment sadrži najmanje 150 amino kiselina proteina MeCP2; i pri čemu spomenuti derivat spomenutog proteina ili fragmenta ima najmanje 60% identičnosti sa spomenutim proteinom MeCP2 ili njegovim fragmentom; i pri čemu spomenuti fragment ili spomenuti derivat ima najmanje 60% spomenuto biološke aktivnosti, kako je određeno transkripcijskim ispitivanjem in vitro opisanim prema Nan, X et al., Cell 88: 471-481 (1997).
A pharmaceutical composition comprising a compound of any of claims 1 to 18 or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav koji sadrži spoj prema jednom od zahtjeva 1 do 18 ili njegovu farmaceutski prihvatljivu sol.
A pharmaceutical composition for rectal administration comprising as active ingredient a salt of claim 1, together with a pharmaceutically acceptable carrier, wherein the composition is in the form of a suppository or microenema, and wherein the composition contains from 0.5 to 40% by weight of the active ingredient. 
Farmaceutski sastav, naznačen time, da on kao aktivni sastojak sadrži jednu od soli prema bilo kojem zahtjevu 1 do 4, koji sastav je predviđen za rektalno davanje i on je u obliku čepića ili mikroenema, koji sastav sadrži od 0,5 do 40 mas. % aktivnog sastojka 1 farmaccutski prihvatljiv nosač.
A process according to claim 11, further comprising the following step: desorbing water from the saturated water vapour sorbent obtained in step b) by heating the saturated water vapour sorbent using the heat produced in step j) to obtain regenerated water vapour sorbent and steam. 
Postupak sukladno Zahtjevu 11, nadalje sadrži sljedeći korak: k) desorpcija vode iz zasićene vodene pare sorpcijskog sredstva dobivenog u koraku b) zagrijavanjem zasićenog sorpcijskog sredstva vodene pare pomoću topline proizvedene u koraku j) kako bi se dobilo regenerirano sorpcijsko sredstvo vodene pare i para.
The method according to claim 11 wherein the composition is a dry powder and the carrier is a saccharide. 
Uporaba prema zahtjevu 13, naznačena time, da sastav lijeka je suhi prašak i nosač je saharid.
time-deinterleaving the extracted constellation values corresponding to Layer 1 signaling data; demapping the time-deinterleaved constellation values corresponding to Layer 1 signaling data into Layer 1 signaling data; 
vađenje vremenski među-pohranjenih vrijednosti skupa iz mape koje odgovaraju sloju 1 odašiljanih podataka u sloj 1 odašiljanih podataka;
phosphate Phosphoric acid 
6.8 mg Fosforna kiselina
Once again, suitable protecting groups for any reactive substituent groups will be well-known to those skilled in the art. 
Ponovno, prikladne zaštitne skupine za bilo koje reaktivne supstituentne skupine bit će dobro poznate stručnim osobama iz odgovarajućeg područja.
A method according to claim 1 wherein said enzyme catalyst is selected from the group consisting of NIT-101, NIT-102, NIT-103 and nitrilase from Arabidopsis thaliana. 
Postupak u skladu s patentnim zahtjevom 4, gdje navedeni enzimski katalizator se bira iz skupine koju čine NIT101, NIT-102, NIT-103 initrilaza iz biljke Arabidopsis thaliana. t>&
A method for delivery of messenger RNA (mRNA) for in vivo production of a protein, comprising administering, to a human, a composition comprising an mRNA that encodes the protein wherein the mRNA is encapsulated within a lipid nanoparticle, wherein the administering of the composition results in expression of the protein encoded by the mRNA that is detectable in serum at least 72 hours after administration, and wherein the lipid nanoparticle comprises one or more PEG-modified lipids. 
Sastav koji sadrži (a) najmanje jednu molekulu mRNA čiji najmanje jedan dio kodira funkcionalni izlučeni polipeptid; i (b) liposomalni nosač za prijenos koji sadrži lipidnu nanočesticu koja sadrži jedan ili više kationskih lipida, jedan ili više nekationskih lipida i jedan ili više lipida modificiranih s PEG, za upotrebu u postupku liječenja subjekta s oštećenjem ili nedostatkom u navedenom izlučenom polipeptidu, pri čemu je mRNA kapsulirana u nosač za prijenos i pri čemu se sastav primjenjuje isporukom u pluća putem nebulizacije.
The two phases were then mixed with a disperser for about 15 minutes. 
Dvije faze se zatim miješaju mikserom oko 15 minuta.
at least one curing agent comprising (b1) at least one cycloaliphatic amine, and 
najmanje jedno sredstvo za stvrdnjavanje koje sadrži (b1) najmanje jedan cikloalifatski amin, i (b2) najmanje jedan polieteramin.
is hydrogen or a nitrogen protecting group selected from t-butoxycarbonyl, benzoyl, styryl, 1-butenyl, benzyl, p-methoxybenzyl and pyrrolidinylmethyl; and R4 is selected from t-butyl, methyl, isopropyl and phenyl. 
(4) Dz gdje je R1 vodikova ili dušikova zaštitna grupa odabrana od t-butoksikarbonila, benzoila, stirila, 1-butenila, benzila, p- metoksibenzila 1 pirolidinilmetila; i
In a method according to the invention the pre-expanded polymer beads are steamed in the casting mould. 
Postupak prema zahtjevu 1, naznačen time što se pred-ekspandirane polimerne kuglice prethodno zagrijavaju prije nego se uvode u kalup za lijevanje.
administering to the subject an anti-CD47 agent that reduces the binding of CD47 on a hepadna virus infected cell, to SIRPa on a phagocytic cell, at an effective dose for increasing the phagocytosis of the hepadna virus infected cell. 
davanje subjektu anti-CD47 agensa koji smanjuje vezivanje CD47 na inficiranoj stanici sa SIRPa na fagocitnoj stanici, u efektivnoj dozi za povećanje fagocitoze inficirane stanice, gdje anti-CD47 agens je:
A wellbore servicing apparatus (100), comprising: a first mandrel (228) movable longitudinally along a central axis and rotatable about the central axis; 
Uređaj (100) za servisiranje kanala bušotine, sadrži: prvi mandrel (228) pomičan longitudinalno duž središnje osi te Totatabilan oko središnje osi;
165 g/l or 170 g/l, to which no sugar or surfactant has been added then the method is operated with an applied pressure of 1.45 bar or more, in another of 1.5 bar or more. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da otopina imunoglobulina ima koncentraciju od 160 g/l ili više, te se nanošenje na kombinaciju filtera vrši primjenom tlaka od 1,45 bara ili više.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
R4 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i
The method of embodiment 4 wherein the pH is about 1 pH unit below the pI of the polypeptide. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je pH otprilike 1 pH jedinica ispod pI protutijela.
(xiii) a peroxisome proliferator-activated receptor (PPAR) agonist, or a pharmaceutically-acceptable salt, solvate or pharmaceutically functional derivative thereof; 
(xiii) agonist peroksisomalno proliferatorom aktiviranog receptora (PPAR), ili njegovu farmaceutski prihvatljivu sol, solvat ili njihov farmaceutski funkcionalni derivat;
A compound according to any one of claims 1 to 3, or a pharmaceutical composition according to any one of claims 4 to 20 for use in inhibiting the growth or differentiation of a Cancer Stem Cell (CSC), a tumor initiating cell, a mesenchymal-like cell associated with cancer, a mesenchymal cancerous cell, or a mesenchymal cell. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 4 do 20, naznačen time, da je namijenjen upotrebi u inhibiranju rasta ili diferencijacije kancerogene matične stanice (CSC), stanice koja inicira tumor, mezenhimalne stanice povezane s rakom, mezenhimalne kancerozne stanice ili mezenhimalne stanice.
Patent US 5 982 593 discloses a circuit breaker incorporating a ground fault protection: such protection is further provided with a test circuit for testing the safe working of the protection circuit itself; such te st circuit is however enabled with a test-button. 
Patent US 5 982 593 opisuje prekidač koji sadrži zaštitu od dozemnog spoja: takva zaštita je opremljena i s krugom za testiranjem sigurnog rada samog zaštitnog kruga; ipak, takav krug za testiranje ima gumb za testiranje.
A pharmaceutical composition as claimed in claim 13, which is an agent for lowering serum uric acid level. 
Farmaceutska smjesa prema zahtjevu 13, koja je inhibitor proizvodnje urične kiseline.
As already mentioned above, as a rule, the gluing is also carried out holohedrally, that is not only the pieces of wood are glued holohedrally among each other by means of an adhesive however, the pieces of material being different from wood are also glued holohedrally among each other and with adjoining pieces of wood. 
Kao što je već bilo gora navedeno kao pravilo, lijepljenje se također izvodi po cijeloj površini, i to ne samo da se međusobno lijepe po cijeloj površini komadi od drva jedni s drugima pomoću ljepila, već se i komadi od materijala koji je različit od drva također međusobno lijepe po cijeloj površini jedni s drugima, a također i sa susjednim komadima koji su od drva.
annealing the first complementary sequence of the joiner oligo to the first digested nucleic acid and the second complementary sequence of the joiner oligo to the second digested nucleic acid; and 
sparivanje prve komplementarne sekvence spojnog oligonukleotida sa prvom digestiranom nukleinskom kiselinom i druge komplementarne sekvence spojnog oligonukleotida sa drugom digestiranom nukleinskom kiselinom; i
The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 6, wherein R4 is a methyl group, a fluoromethyl group, a difluoromethyl group, a hydroxymethyl group or a methoxy group. 
Spoj ili njegova farmaceutski prihvatljiva kisela adicijska sol prema zahtjevu 6, pri čemu Ru je metilna skupina, fluorometilna skupina, difluorometilna skupina, hidroksimetilna skupina ili metoksi skupina. HR P20181349 T1
LFM-A13, wherein the BTK gene encodes a protein isoform having a molecular weight between 65 and 68 kDa of the amino acid sequence SEQ ID NO:2 
LFM-A13, pri čemu BTK gen kodira izoformu proteina sa molekularnom težinom između 65 i 68 kDa, aminokiselinske sekvence SEQ ID NO:2
a protein-binding segment that interacts with a Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides; wherein the first nucleotide sequence encoding said DNA-targeting RNA is operably linked to a promoter; and, optionally, 
(ii) segment koji se veže na proteine koji međudjeluje s polipeptidom Cas9, gdje segment koji se veže na proteine sadrži dva komplementarna odsječka nukleotida koji hibridiziraju kako bi tvorili dvolančani RNA (AsRNA) dupleks; gdje je prvi nukleotidni slijed, koji kodira navedena RNA koja cilja na DNA, operabilno spregnut s promotorom; i, izborno, so HR P20190965 T1
and R13 are taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from one O, one S, and up to 2 N, wherein up to 2 carbon atom ring members are independently selected from C(=O) and C(=S) and the sulfur atom ring member is selected from S, S(O) or S(O)2, said ring optionally substituted with up to 4 substituents independently selected from the group consisting of halogen, cyano and C1-C4 alkyl; 
i R13 su uzeti zajedno sa atomom dušika za koji su vezani tako da formiraju 3- do 7-člani prsten koji sadrži članove prstena izabrane od atoma ugljika i do 2 heteroatoma nezavisno izabrana od jednog O, jednog S i do 2 N, gdje su do 2 člana prstena atoma ugljika izabrana od C(=O) i C(=S) i atom sumpora član prstena je izabran od S, S(O) ili S(O)2, pri čemu je navedeni prsten izborno supstituiran sa do 4 supstituenta nezavisno izabrana iz grupe koju čine halogen, cijano i C1-C4 alkil;
A transport unit according to any one of the previous claims, wherein the mineral wool plates of the mineral wool plate package are parallelepiped-shaped or rectangular cuboids stacked upon each other to form a substantially parallelepiped-shaped stack of mineral wool plates. 
Transportna jednica sukladno bilo kojem od prethodnih zahtjeva, pri čemu ploče mineralne vune (2) pakiranja ploča mineralne vune(1) su oblika paralelopipeda ili pravokutnih kuboida složenih jedan na drugi kako bi se formiralo skupinu ploča mineralne vune (2) oblika paralelopipeda .
In another aspect is a pharmaceutical composition comprising a compound of Formula (I) and Formula (II) or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvate and a pharmaceutically acceptable carrier, excipient, binder or diluent thereof. 
Farmaceutski pripravak koji sadrži spoj prema zahtjevu 1 formule F a" ili njegovu farmaceutski prihvatljivu sol ili farmaceutski prihvatljiv solvat 1 farmaceutski prihvatljiv nosač, ekscipijens, vezivno sredstvo ili otapalo.
A plastic film according to claim 5 comprising at least 70 weight percent aliphatic polycarbonate, characterized in that the film has elongation before break value as measured by ASTM D882 of at least 100%. The plastic film of claim 7, wherein 
Plastični film u skladu s patentnim zahtjevom 5, koji sadržava barem 70 % težinskih udjela alifatskog polikarbonata, naznačen time, da film ima produljenje prije vrijednosti loma, izmjereno u skladu s ASTM D882, barem 100 %.
provided that if A and B are fused to and take the part of positions 2 and 3 of an unsubstituted indole, n is 1 or 2, R2 and R3 are H, m is 1 and R1 is in position 6 of the spiro oxindole, then 
A 1B su kondenzirani na nesupstituirani ili supstituirani indol i tvore dio njega; pod uvjetom da ako su A 1 B kondenzirani na pozicijama 2 1 3 od nesupstituiranog indola, nje 11ili2, R21R3 suH, mje liR1 je na poziciji 6 od spiro-oksindola, tada
is absent, -NH-, -SO2- or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy); 
je odsutan, -NH-, -SO2- ili alkil (pri čemu je alkil po izboru supstituiran u jednom ili više položaja s halogenom, hidroksi, nižim alkil, nižim alkoksi, karboksi ili karbonilalkoksi);
An example of an HDL raising agent is nicotinic acid, but the quantities needed to achieve HDL elevation are associated with undesirable effects, such as flushing. 
Primjer sredstva za povišenje razine HDL je nikotinska kiselina, no količine potrebne za postizanje porast HDL su povezane s nepoželjnim učincima, poput crvenila u licu.
or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (5), or a pharmaceutically acceptable salt thereof. 
(4 ili njegove farmaceutski prihvatljive soli, u uvjetima pogodnim za dobivanje spoja formule (5), ili njegove farmaceutski prihvatljive soli.
A method for making lasagne and other ready to eat products, according to one or more of the preceding claims, characterized in that said pasteurizing step comprises a hot air pasteurizing treatment, followed by a cooling treatment on conveyor belts arranged with a spiral arrangement in heating and cooling towers. 
Postupak prema zahtjevu 1, naznačen time što korak pasteriziranja obuhvaća pasterizacijsku obradu vrućim zrakom, nakon čega slijedi hlađenje na pokretnim trakama koje su spiralno smještene u tornjevima za grijanje i hlađenje.
A pharmaceutical combination comprising: 
Farmaceutska kombinacija koja sadrži
A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 14 and a pharmaceutically acceptable carrier or excipient. 
Sastav koji sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegove farmaceutske prihvatljive soli i farmaceutski prihvatljivog nosača ili ekscipijensa.
The method of Claim 1, wherein said bacteriophage either is a naturally occurring bacteriophage or is a mutated bacteriophage obtained through selective pressure using a bacteriophage resistant bacterium. 
Postupak prema zahtjevu 1, naznačen time da navedeni bakteriofag je ili bakteriofag koji se javlja u prirodi ili je mutirani bakteriofag dobiven pomoću selektivnog pritiska korištenjem bakterije rezistentne na bakteriofag.
The use of an ophthalmic composition according to claims 1-10 for the preparation of a medicament for the treatment of HSV-epithelial keratitis, HSV-stromal keratitis, ocular complications of herpes zoster ophthalmicus. 
Primjena oftalmičkog pripravka prema patentnim zahtjevima 1-10, naznačena time da je za pripravu lijeka za tretman sljedećih: HSV-epitelni keratitis, HSV-stromalni keratitis, okularne komplikacije od herpes zoster ophthalmicus.
the surfaceof each of said nonmagnetic members (13) facing the center axis side of said ring members (11, 12); and 
što je površina svakog od ne-magnetskih članova (13) okrenuta prema središnjoj osnoj strani prstenastih članova
FIELD OF THE INVENTION The present invention provides an antibiotic composition comprising coated micropellets. 
Područje izuma Prikazani izum osigurava antibiotski pripravak koji sadrži obložene mikropelete klaritromicina.
An IL-17 binding antibody or fragment thereof comprising both heavy (VH) and light chain (VL) variable domains; said IL-17 binding molecule comprises at least one antigen binding site comprising: 
IL-17-vezivno protutijelo ili njegov fragment, naznačeno time, da obuhvaća varijabilne domene kako teškog lanca (VH) tako i lakog lanca (VL), za uporabu u liječenju upalnog artritisa, pri čemu spomenuto IL-17-vezivno protutijelo ili njegov fragment sadrži najmanje jedno mjesto za vezanje antigena, koje obuhvaća sljedeće:
A compound according to any one of the preceding claims for use as a pharmaceutical. A compound according to any one of Claims 1-4 in combination with an anti-inflammatory, bronchodilatory, anti-histamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition. 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili njegovi stereoizomeri ili njegove farmaceutski prihvatljive soli, naznačen time, da se upotrebljava u kombinaciji s s anti-upalnom, bronhodilatornom, anti-histaminskom ili antitusivnom ljekovitom tvari, pri čemu su spomenuti spoj i spomenuta ljekovita tvar u istom ili u različitom farmaceutskom sastavu.
A liquid pharmaceutical formulation comprising: about 50 to about 200 grams of deferiprone per liter of the formulation, about 15 grams of sucralose per liter of the formulation, about 500 grams of glycerin per liter of the formulation, about 1 gram of hydroxyethylcellulose per liter of the formulation, about 59 grams of concentrated hydrochloric acid per liter of the formulation, about 0.40 grams of FD&C Yellow No. 
Ukusna tekuća farmaceutska formulacija prema zahtjevu 1 koja sadrži: oko 50-200 grama deferiprona po litri formulacije, oko 15 grama sukraloze po litri formulacije, oko 500 grama glicerina po litri formulacije, oko 1 gram hidroksietilceluloze po litri formulacije, oko 59 grama koncentrirane klorovodične kiseline po litri formulacije, oko 0.40 grama FD&C Yellow No.
reacting said purified Compound 8 with a secondary amine and a carboxylic acid in a first solvent to produce Compound 10: and, 
reakciju navedenog prečišćenog spoja 8 sa sekundarnim aminom i karboksilnom kiselinom u prvom otapalu da se proizvede spoj 10.
an individual for whom the monotherapy with metformin is contraindicated and/or who has an intolerance against metformin at therapeutic doses; or an individual with insufficient glycemic control despite monotherapy with a SGLT2 inhibitor; or 
Farmaceutski sastav za uporabu prema zahtjevu 11, 12 ili 13, naznačen time, da je pacijent pojedinac kod kojega je kontraindicirana monoterapija s metforminom i/ili koji nema toleranciju protiv metformina u terapeutskim dozama.
The other lipid agent or lipid-modulating agent may be a cholesteryl transfer protein inhibitor (CETP) such as Pfizer's CP-529,414 as well as those disclosed in WO/0038722 and in EP 818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795, as well as CETi-1 and JTT-705. 
41, Drugo lipidno sredstvo ili sredstvo za modulaciju lipida može biti inhibitor proteina za prijenos kolesterola (CETP) kao što je Pfizerov CP-529,414 jednako kao i oni izneseni u WO/0038722 i EP 818448 (Bayer) i EP 9924 96 i Pharmaciaev SC-744 i SC-795, jednako kao i CETi-1 i JTT-705.
An intermediate having the formula B-(4). 
Intermedijer naznačen time da ima formulu B-(4).
in part (i), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:131 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:130; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 129 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 128;
A lock and key system as defined in claim 7, wherein said longitudinal code pattern is a wave-like code pattern(125; 185) which is disposed in a longitudinal groove in said side portion. 
Sustav ključa 1 brave kako je definirano u zahtjevu 7, naznačen time da je navedeni uzdužni kodni uzorak valoviti kodni uzorak (125; 185) koji je raspoređen u uzdužnom žlijebu u navedenom bočnom dijelu.
is cyclohexyl, phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal or LA, in Subformula 13 
R? je cikloheksil, fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal ili LA, u Podformuli 13
The use according to claim 9, wherein the psychosis is schizophrenia or a schizo-affective disorder; the drug abuse is alcohol, cocaine, nicotine or opioid abuse; the eating disorder is bulimia nervosa; the dyskinetic disorder is Parkinson's disease, neuroleptic induced parkinsonism or tardive dyskinesia; the sexual dysfunctions is erectile dysfunctions. 
Uporaba prema zahljevu 9, naznačena time, da psihoza je shizofrenija ili shizo-afektivan poremećaj; zlouporaba droga je zlouporaba alkohola, kokaina, nikotina ili opijata; poremećaj hranjenja je neurozna bulimija; diskinetički poremećaj je Parkinson-ova bolest, neuroleptički proizveden parkinsonizam ili tardivna diskinezija, seksualna disfunkcija je erektivna disfunkcija.
A winch according to claim 3 or claim 4 wherein, when the crank handle is located in the drive socket, the motor can be driven in a reverse-winding direction, and non-reverse winding of the winch drum is indicated to the operator by an audible signal. A winch arrangement for a sailboat comprising: 
Vitlo prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da kada je zahvatna ručica smještena u pogonskom grlu, elektromotor se može pogoniti u smjeru povratnog okretanja namatanja, a ne-povratno okretanje namatanja bubnja vitla, naznačava se korisniku pomoću zvučnog signala.